Pediatrics
This session reviews and update core principles of treating patients with pediatric malignancies including Wilms tumor, Ewing sarcoma, rhabdomyosarcoma, embryonal central nervous system tumors, CNS ependymoma, central nervous system germinomas, central nervous system non-germinomatous germ cell tumor, and diffuse midline glioma. The session includes case presentations and describe variations in practice.
Target Audience
The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Describe the workup of Ewing Sarcoma and Rhabdomyosarcoma, and describe the timings, fields, dose and fractionation of radiation therapy for localized disease of these two disease entities.
- Compare and contrast the disease findings of average risk medulloblastoma and high risk medulloblastoma, and discuss the timing, radiation fields, doses and fractionation for both.
- Discuss the natural history of diffuse midline gliomas and the role of radiation therapy in its treatment (including timing, fields, dose and fractionation).
Speaker
- Ralph Ermoian, MD, University of Washington
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.

Facebook
X
LinkedIn
Forward